The U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) today submitted a landmark proposed rulemaking to the Federal Register, mandating immediate 21 CFR Part 607 establishment registration and drug listing for all foreign manufacturing facilities synthesizing (S)-isomer and racemic nicotine exported into the United States.
The new enforcement framework closes a critical regulatory loophole created during the 2022 Clarifying Authority Over Non-Tobacco Nicotine Act. Under the proposed rule, foreign chemical synthesis plants in China, India, and Switzerland will no longer be permitted to clear U.S. Customs and Border Protection (CBP) ports of entry under generic chemical harmonized tariff codes without verified FDA Establishment Identifier (FEI) numbers and active Drug Master Files (DMF).
According to internal agency memoranda reviewed by NicotineWire, CBP Import Alert #99-43 has been updated to include red-list detention without physical examination for non-compliant bulk liquid shipments exceeding 99.0% purity standards. Market analysts project immediate supply chain disruption across 14 major oral pouch contract manufacturers that rely on unlisted overseas synthesis suppliers.
Facilities cited in the preliminary detention annex include key synthesis hubs across Shenzhen and Gujarat. Importers will be given a 45-day window following official Federal Register publication to submit corrective Section 905(b) registrations or face mandatory cargo re-exportation and civil money penalties under 21 U.S.C. 333(f).